Caricamento...
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
OBJECTIVE: To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti‐acetylcho...
Salvato in:
| Pubblicato in: | Ann Clin Transl Neurol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7448154/ https://ncbi.nlm.nih.gov/pubmed/32700461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51121 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|